Free Access
Med Sci (Paris)
Volume 32, Number 2, Février 2016
Page(s) 141 - 143
Section Nouvelles
Published online 02 March 2016
  1. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 2014 ; 32 : 513–545. [CrossRef] [PubMed] [Google Scholar]
  2. Meraz MA, White JM, Sheehan KC, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996 ; 84 : 431–442. [CrossRef] [PubMed] [Google Scholar]
  3. Fink K, Grandvaux N. STAT2 and IRF9: Beyond ISGF3. JAKSTAT 2013 ; 2 : e27521. [PubMed] [Google Scholar]
  4. Blaszczyk K, Olejnik A, Nowicka H, et al. STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. Biochem J 2015 ; 466 : 511–524. [CrossRef] [PubMed] [Google Scholar]
  5. Johnson ES. Protein modification by SUMO. Annu Rev Biochem 2004 ; 73 : 355–382. [CrossRef] [PubMed] [Google Scholar]
  6. Lamoliatte F, Caron D, Durette C, et al. Large-scale analysis of lysine SUMOylation by SUMO remnant immunoaffinity profiling. Nat Commun 2014 ; 5 : 5409. [CrossRef] [PubMed] [Google Scholar]
  7. Begitt A, Droescher M, Knobeloch KP, Vinkemeier U. SUMO conjugation of STAT1 protects cells from hyperresponsiveness to IFNgamma. Blood 2011 ; 118 : 1002–1007. [CrossRef] [PubMed] [Google Scholar]
  8. Maarifi G, Maroui MA, Dutrieux J, et al. Small ubiquitin-like modifier alters IFN response. J Immunol 2015 ; 195 : 2312–2324. [CrossRef] [PubMed] [Google Scholar]
  9. Chelbi-Alix MK, Quignon F, Pelicano L, et al. Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol 1998 ; 72 : 1043–1051. [PubMed] [Google Scholar]
  10. Geoffroy MC, Chelbi-Alix MK. Role of promyelocytic leukemia protein in host antiviral defense. J Interferon Cytokine Res 2011 ; 31 : 145–158. [Google Scholar]
  11. Regad T, Chelbi-Alix MK. PML, un nouvel intermédiaire de l’effet antiviral de l’interféron. Med Sci (Paris) 2002 ; 18 : 25–27. [CrossRef] [EDP Sciences] [Google Scholar]
  12. Maroui MA, El Asmi F, Dutrieux J, et al. Implication des corps nucléaires PML dans l’immunité intrinsèque et innée. Med Sci (Paris) 2014 ; 30 : 765–771. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  13. Tatham MH, Geoffroy MC, Shen L, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008 ; 10 : 538–546. [CrossRef] [PubMed] [Google Scholar]
  14. Maroui MA, Kheddache-Atmane S, El Asmi F, et al. Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms. PLoS One 2012 ; 7 : e44949. [CrossRef] [PubMed] [Google Scholar]
  15. El Bougrini J, Dianoux L, Chelbi-Alix MK. PML positively regulates interferon gamma signaling. Biochimie 2011 ; 93 : 389–398. [CrossRef] [PubMed] [Google Scholar]
  16. Maroui MA, Pampin M, Chelbi-Alix MK. Promyelocytic leukemia isoform IV confers resistance to encephalomyocarditis virus via the sequestration of 3D polymerase in nuclear bodies. J Virol 2011 ; 85 : 13164–13173. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.